---
title: "DMT Drug Trial Could Revolutionise Treatment for Problem Drinkers in Britain"
publisher: "Stockmark.IT"
author: "Stockmark.IT Website"
published: "2025-01-20T06:23:45+00:00"
modified: "2025-01-20T06:23:45+00:00"
date: 2025-01-20
canonical: "https://stockmark.it/dmt-drug-trial-could-revolutionise-treatment-for-problem-drinkers-in-britain/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
image: "https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-it-6-2.jpg?fit=1200%2C800&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# DMT Drug Trial Could Revolutionise Treatment for Problem Drinkers in Britain

**Published:** January 20, 2025
**Author:** Stockmark.IT Website
**Categories:** Healthcare, Pharmaceutical
**Featured image:** ![Glass coffee maker with brewed coffee. Wooden collar with leather tie. from Stockmark.it](https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-it-6-2.jpg?fit=1200%2C800&quality=89&ssl=1)

---

A groundbreaking clinical trial at University College London (UCL) is poising to transform the landscape of alcohol misuse treatment through the utilisation of dimethyltryptamine (DMT), a potent psychedelic compound. The market implications for pharmaceutical companies specialising in addiction therapeutics could be substantial, as current treatment protocols demonstrate limited efficacy.

The investment potential in this sector becomes apparent when examining the existing treatment success rates. Current methodologies result in a 50% relapse rate within three months, escalating to 70% within three years. These statistics represent a significant market gap for innovative therapeutic solutions.

The trial, valued at an undisclosed sum, will involve 120 participants, establishing it as the largest psychedelic brain imaging study to date. The research protocol involves administering DMT intravenously, with effects lasting approximately 15 minutes. The controlled environment and precise dosing methodology distinguish this approach from traditional therapeutic interventions.

Market analysts should note that DMT, the active ingredient in ayahuasca, has demonstrated promising preliminary results. The treatment’s brief duration could present a competitive advantage over existing therapies, potentially reducing healthcare delivery costs and improving patient compliance.

The research team, led by Professor Ravi Das and Professor Jeremy Skipper, has implemented rigorous controls, including MRI brain scanning while participants view specific alcohol-related media content. The nine-month follow-up period will provide crucial data for potential commercialisation strategies.

The pharmaceutical sector should monitor this development closely, as successful trial outcomes could lead to phase 3 clinical trials. With global alcohol misuse rates continuing to rise, despite perceived generational shifts in consumption patterns, the market opportunity for effective treatments remains substantial.

---

**Original URL:** https://stockmark.it/dmt-drug-trial-could-revolutionise-treatment-for-problem-drinkers-in-britain/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*